Form 4: PTC Therapeutics Director Stephanie Okey Acquires Shares and Options
SEC Form 4 Filing
Director Stephanie Okey of PTC Therapeutics acquired 4,000 shares of common stock and 8,800 stock options on January 3, 2025.
Summary
- Stephanie Okey, a director at PTC Therapeutics, acquired 4,000 shares of common stock on January 3, 2025.
- These shares were acquired at a price of $0, likely as part of a compensation package.
- Okey also acquired 8,800 stock options on the same date, with an exercise price of $46.54.
- The stock options vest over one year in twelve equal monthly installments, starting February 3, 2025.
- The restricted stock units vest over one year, with a portion vesting on June 17, 2025, and the remainder on January 3, 2026.
Sentiment
Score: 6
Explanation: The document reflects a routine transaction by a company director. It is neither particularly positive nor negative, but rather a standard disclosure.
Positives
- The acquisition of shares and options by a director could be seen as a positive sign of confidence in the company's future.
Industry Context
This is a standard SEC Form 4 filing, which is common for publicly traded companies when insiders make transactions in their company's stock. It is a routine disclosure and does not indicate any specific industry trend.
Comparison to Industry Standards
- Stock option and restricted stock unit grants are common forms of compensation for directors and executives in publicly traded companies, particularly in the biotechnology sector.
- The vesting schedules described are typical, with vesting periods designed to incentivize long-term performance and retention.
- The exercise price of $46.54 for the stock options is a standard practice, often set at or near the market price at the time of grant.
- Companies like Regeneron, Biogen, and Vertex Pharmaceuticals also use similar compensation structures for their directors and executives.
Stakeholder Impact
- The transaction has a minor positive impact on shareholders as it indicates director confidence in the company.
Key Dates
| Date | Description |
|---|---|
| 01/03/2025 | Date of the transaction where shares and stock options were acquired. |
| 02/03/2025 | Start date for the monthly vesting of the stock options. |
| 06/17/2025 | Date when five-twelfths of the restricted stock units vest. |
| 01/03/2026 | Date when the remaining seven-twelfths of the restricted stock units vest. |
| 01/02/2035 | Expiration date of the stock options. |
| 01/07/2025 | Date the form was signed. |
Keywords
PTC Therapeutics, Director, Stock Options, Restricted Stock Units, Share Acquisition, Insider Trading, Form 4
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.